Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Publisher： Karger

E-ISSN： 1423-0267|233|2|66-73

ISSN： 0030-3755

Source： Ophthalmologica, Vol.233, Iss.2, 2014-11, pp. : 66-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 200-206

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration

By Patel Ravi D.   Momi Rominder S.   Hariprasad Seenu M.  

Seminars in Ophthalmology, Vol. 26, Iss. 6, 2011-11 ,pp. : 372-379

Informa Healthcare

Access to resources Recommend Favorite